Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2026)

Crinetics Pharmaceuticals has reported Common Equity for 10 years, with the latest figure at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 2.12% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 2.12% YoY), and the FY2025 full-year result was $992.1 million, down 25.11% from the prior year.
• Common Equity for Q1 2026 stood at $1.3 billion, up from $992.1 million in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q4 2024, with the low at $254.1 million in Q2 2023.
• Average Common Equity over 5 years is $741.9 million, with a median of $830.8 million recorded in 2024.
• Year-over-year, Common Equity slumped 34.19% in 2023 and surged 226.92% in 2024.
• Tracing CRNX's Common Equity over 5 years: stood at $316.3 million in 2022, then jumped by 70.43% to $539.1 million in 2023, then soared by 145.74% to $1.3 billion in 2024, then decreased by 25.11% to $992.1 million in 2025, then advanced by 29.09% to $1.3 billion in 2026.
• The last three Common Equity figures came in at $1.3 billion (Q1 2026), $992.1 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison